Xin Lang Cai Jing·2025-12-25 01:44Core Viewpoint - The article discusses recent legal developments regarding investor claims against Pulil Pharmaceutical and Hainan Huatie, highlighting the outcomes of court rulings and ongoing legal actions related to alleged financial misconduct by these companies. Group 1: Pulil Pharmaceutical - On December 23, 2025, the Haikou Intermediate People's Court ruled in favor of investors in a claim against Pulil Pharmaceutical, with the legal team continuing to accept further claims from other investors [1][4]. - Pulil Pharmaceutical was found to have overstated its revenue by approximately 514.6 million yuan in 2021, which accounted for 34.11% of the reported revenue for that year, and by about 515.9 million yuan in 2022, representing 28.56% of the reported revenue for that year [1][4]. - The company also overstated its total profit by 308 million yuan in 2021 (65.88% of reported profit) and by 387.4 million yuan in 2022 (88.27% of reported profit) [1][4]. Group 2: Hainan Huatie - Hainan Huatie's investor claims are also being pursued, with a new case submitted to the Hangzhou Intermediate People's Court on December 23, 2025, following previous submissions [2][5]. - The company received a notice from the China Securities Regulatory Commission on October 16, 2025, regarding an investigation into alleged violations of information disclosure laws [2][5]. - Hainan Huatie announced the termination of a "Computing Power Service Agreement" with a subsidiary, citing significant changes in market conditions and a lack of purchase orders since the contract was signed [3][6].